Filing Flows › Comparisons › ABUS vs STTK
Arbutus Biopharma vs Shattuck Labs: ABUS and STTK compared
Arbutus Biopharma is the larger company: $1.0M of revenue in its latest quarter (Q2 2026) against $1.0M for Shattuck Labs (Q3 2025). Shattuck Labs is growing faster (-67% against -91% a year earlier).
Where the money goes: ABUS and STTK
Arbutus Biopharma (ABUS) · Q2 2026
Arbutus Biopharma, Q2 2026: revenue $1.0M (-91% year over year), operating margin -588.2%, net loss $5.1M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
Shattuck Labs (STTK) · Q3 2025
Shattuck Labs, Q3 2025: revenue $1.0M (-67% year over year), net loss $10.1M, operating cash flow −$8.9M. The chart follows the revenue to costs, profit and cash.
| Arbutus Biopharma (ABUS) | Shattuck Labs (STTK) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2025 |
| Revenue | $1.0M | $1.0M |
| Revenue growth, Y/Y | -91% | -67% |
| Operating margin | -588.2% | n/m |
| Net earnings | −$5.1M | −$10.1M |
| Net margin | -507.2% | — |
| Operating cash flow | −$6.0M | −$8.9M |
Where the revenue comes from
Arbutus Biopharma
- Revenue from collaborations and licenses: $632K (62%)
- Collaborations and licenses: $202K (20%)
- Non-cash royalty revenue: $180K (18%)
Questions
Which is bigger, Arbutus Biopharma or Shattuck Labs?
Arbutus Biopharma is the larger company: $1.0M of revenue in its latest quarter (Q2 2026) against $1.0M for Shattuck Labs (Q3 2025).
Is Arbutus Biopharma or Shattuck Labs growing faster?
Shattuck Labs is growing faster (-67% against -91% a year earlier).
More: Arbutus Biopharma earnings · how Arbutus Biopharma makes money · Shattuck Labs earnings · how Shattuck Labs makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed Nov 6, 2025). Fiscal quarters can end on different dates. Not investment advice.